Vastagbélrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

6+ intézményből 6, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Novel macrophage repolarization therapy for colorectal cancer

  Panorama Research, Inc.· Sunnyvale, Egyesült Államok· 387 240 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIAID · R01

  Impact of bacterial phenotypic variation on phage resistance

  Institute for Systems Biology· Seattle, Egyesült Államok· 874 085 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, Egyesült Államok· 762 815 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NCI · K99

  Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting

  Yale University· New Haven, Egyesült Államok· 168 290 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, Egyesült Államok· 2 541 122 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spanyolország· EU contribution 194 075 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 217 965 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Ausztria· EU contribution 4 281 580 EUR· until 2031. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 990 running projects, newest first. Listed amounts together: 553,9 M USD + 233,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Frissítve: 2026. febr. 19.

  “business objectives have changed”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Frissítve: 2025. szept. 19.

  “Limited resources and strategic priorities”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Day One Biopharmaceuticals, Inc.· Frissítve: 2025. aug. 14.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 317
• Genome-Wide Association Study 65

• [Construction and internal validation of a prognostic prediction model for R0 resection after conversion therapy in colorectal cancer liver metastases based on clinicopathological features combined with ctDNA].

  Zhonghua Yi Xue Za Zhi, 2026. nov.

• Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial.

  BJS Open, 2026. nov.

• Monitoring Molecular Residual Disease in Colorectal Cancer Using Tumor-Informed ctDNA Analysis.

  Oncol Res, 2026. okt.

• Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions.

  Curr Oncol, 2026. okt.

• Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

  Oncologist, 2026. okt.

• Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO.28).

  JCO Precis Oncol, 2026. okt.

• Perioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation.

  J Gastrointest Cancer, 2026. szept.

• Postoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility.

  J Gastrointest Cancer, 2026. szept.

• Liquid Biopsies for Cancer: A Translational Science Review.

  JAMA, 2026. szept.

• Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

  Nat Cancer, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.